Skip to main content
Paul Shami, MD, Hematology, Salt Lake City, UT, University of Utah Health

PaulJ.ShamiMD

Hematology Salt Lake City, UT

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Professor, Internal Medicine, University of Utah School of Medicine

Dr. Shami is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shami's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1994
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1988 - 1991
  • American University of Beirut Faculty of Medicine
    American University of Beirut Faculty of MedicineClass of 1988

Certifications & Licensure

  • UT State Medical License
    UT State Medical License 1997 - 2026
  • NC State Medical License
    NC State Medical License 1991 - 1999
  • MD State Medical License
    MD State Medical License 1990 - 1991
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
    Paul J Shami, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Durham’s Chimerix Pays $30M to Secure Rights for Late-Stage Leukemia Drug
    Durham’s Chimerix Pays $30M to Secure Rights for Late-Stage Leukemia DrugAugust 2nd, 2019
  • Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia
    Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid LeukemiaJuly 31st, 2019
  • Huntsman Cancer Institute Joins Study Aimed at Improving Leukemia Screening, Treatment
    Huntsman Cancer Institute Joins Study Aimed at Improving Leukemia Screening, TreatmentMarch 19th, 2018
  • Join now to see all

Grant Support

  • Preclinical Development Of JS-K, A Novel No-Generating Prodrug For CancerNational Cancer Institute2010–2012
  • Development Of JS-K As An Anti-Leukemic AgentNational Cancer Institute2008–2012
  • Role Of Nitric Oxide In Myelodysplastic SyndromesNational Center For Research Resources2005
  • Genetic Targets Of Nitric Oxide In Leukemia CellsNational Cancer Institute2002–2004
  • NO, Guanylate Cyclase And Immunotherapy Of CancerNational Cancer Institute2000

Professional Memberships

Hospital Affiliations